<DOC>
	<DOC>NCT01333696</DOC>
	<brief_summary>The aim of the study is to evaluate the efficacy and safety of pemetrexed monotherapy as salvage treatment in patients with relapsed or metastatic squamous cell carcinoma of head and neck.</brief_summary>
	<brief_title>Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck</brief_title>
	<detailed_description>The treatment option in patients with platinum-resistant relapsed or metastatic squamous cell carcinoma of head and neck is limited. Previous randomized phase III study showed a borderline benefit of pemetrexed added to cisplatin. Therefore, we aim to evaluate the efficacy of pemetrexed in salvage setting.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Age range: 1865 years old Histological confirmed incurable relapsed or metastatic squamous cell carcinoma of head and neck Prior exposure of at least one line of platinumcontaining regimen At least one site of measurable disease according to RECIST criteria ECOG performance status 01 Life expectancy of more than 3 months Bone marrow function: ANC≧1.5×109/L, PLT≧100×109/L, Hb≧80g/L Liver function: total bilirubin, ALT and AST &lt;1.5×UNL Renal function: Cr&lt;1.5×UNL, CCR≧45ml/min With curable treatment option Prior platinum exposure only in neoadjuvant/adjuvant setting or concurrently used with radiotherapy History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix Significant active infection Pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Squamous cell carcinoma of head and neck</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>